Through the Decades: β-Blocker Use and Outcomes in Acute Coronary SyndromesKukin, Alina; Noel, Zachary, R., PharmD, BCPS; Watson, Kristin, PharmD, BCPSCardiology in Review: May/June 2018 - Volume 26 - Issue 3 - p 157–166 doi: 10.1097/CRD.0000000000000197 Feature Curbside Consult Abstract Author Information Beta-adrenergic receptor antagonists, or β-blockers, have been a cornerstone of treatment in patients with acute coronary syndromes (ACS) for more than 4 decades. First studied in the 1960s, β-blockers in ACS have been shown to decrease the risk of death, recurrent ischemic events, and arrhythmias by reducing catecholamine-mediated effects and reducing myocardial oxygen demand. Through the decades, the β-blocker of choice, timing of initiation, duration of therapy, and dosing have evolved considerably. Despite having clear benefits in certain patient populations (eg, patients with systolic dysfunction who are hemodynamically stable), the benefit of β-blockers in other populations (ie, in patients at low risk for complications receiving modern revascularization therapies and optimal medical management) remains unclear. This article provides a review of the landmark clinical trials of β-blockers in ACS and highlights the chronology and evolution of guideline recommendations through the decades. From the Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy, Baltimore, MD. Disclosure: The authors declare no conflicts of interest. Correspondence: Zachary R. Noel, PharmD, BCPS, Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy, 20 North Pine Street, S427 Baltimore, MD. E-mail: firstname.lastname@example.org. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.